Search

Your search keyword '"Syngelaki, Argyro"' showing total 624 results
Start Over Author "Syngelaki, Argyro"
624 results on '"Syngelaki, Argyro"'

1. Machine learning-enabled maternal risk assessment for women with pre-eclampsia (the PIERS-ML model): a modelling study

Author

Brown, Mark A., Davis, Gregory K., Parker, Claire, Walters, Barry N., Sass, Nelson, Ansermino, J. Mark, Cao, Vivien, Cundiff, Geoffrey W., von Dadelszen, Emma C.M., Douglas, M. Joanne, Dumont, Guy A., Dunsmuir, Dustin T., Hutcheon, Jennifer A., Joseph, K.S., Lalji, Sayrin, Lee, Tang, Li, Jing, Lim, Kenneth I., Lisonkova, Sarka, Lott, Paula, Menzies, Jennifer M., Millman, Alexandra L., Palmer, Lynne, Payne, Beth A., Qu, Ziguang, Russell, James A., Sawchuck, Diane, Shaw, Dorothy, Still, D. Keith, Ukah, U. Vivian, Wagner, Brenda, Walley, Keith R., Hugo, Dany, Gruslin, The late Andrée, Tawagi, George, Smith, Graeme N., Côté, Anne-Marie, Moutquin, Jean-Marie, Ouellet, Annie B., Lee, Shoo K., Duan, Tao, Zhou, Jian, Haniff, The late Farizah, Mahajan, Swati, Noovao, Amanda, Karjalainend, Hanna, Kortelainen, Alja, Laivuori, Hannele, Ganzevoort, J. Wessel, Groen, Henk, Kyle, Phillipa M., Moore, M. Peter, Pullar, Barbra, Bhutta, Zulfiqar A., Qureshi, Rahat N., Sikandar, Rozina, Bhutta, The late Shereen Z., Cloete, Garth, Hall, David R., van Papendorp, The late Erika, Steyn, D. Wilhelm, Biryabarema, Christine, Mirembe, Florence, Nakimuli, Annettee, Allotey, John, Thangaratinam, Shakila, Nicolaides, Kypros H., Ionescu, Olivia, Syngelaki, Argyro, de Swiet, Michael, Magee, Laura A., von Dadelszen, Peter, Akolekar, Ranjit, Walker, James J., Robson, Stephen C., Broughton-Pipkin, Fiona, Loughna, Pamela, Vatish, Manu, Redman, Christopher W.G., Barry, Sarah J.E., Kavanagh, Kimberley, Montgomery-Csobán, Tunde, Murray, Paul, Robertson, Chris, Tsigas, Eleni Z., Woelkers, Douglas A., Lindheimer, Marshall D., Grobman, William A., Sibai, Baha M., Merialdi, Mario, Widmer, Mariana, Montgomery-Csobán, Tünde, Barry, Sarah J E, Vivian Ukah, U, Payne, Beth A, Nicolaides, Kypros H, Hutcheon, Jennifer A, and Magee, Laura A

Published
2024
Full Text
View/download PDF

10. GWAS meta-analysis of intrahepatic cholestasis of pregnancy implicates multiple hepatic genes and regulatory elements

Author

Dixon, Peter H., Levine, Adam P., Cebola, Inês, Chan, Melanie M. Y., Amin, Aliya S., Aich, Anshul, Mozere, Monika, Maude, Hannah, Mitchell, Alice L., Zhang, Jun, Chambers, Jenny, Syngelaki, Argyro, Donnelly, Jennifer, Cooley, Sharon, Geary, Michael, Nicolaides, Kypros, Thorsell, Malin, Hague, William M., Estiu, Maria Cecilia, Marschall, Hanns-Ulrich, Gale, Daniel P., and Williamson, Catherine

Published
2022
Full Text
View/download PDF

14. Artificial Intelligence to Assist in the Screening Fetal Anomaly Ultrasound Scan (PROMETHEUS): A Randomised Controlled Trial

Author

Day, Thomas George, primary, Matthew, Jacqueline, additional, Budd, Samuel F, additional, Farruggia, Alfonso, additional, Venturini, Lorenzo, additional, Wright, Robert, additional, Jamshidi, Babak, additional, To, Meekai, additional, Ling, Huazen, additional, Lai, Jonathon, additional, Tan, Min Yi, additional, Brown, Matthew, additional, Guy, Gavin, additional, Casagrandi, Davide, additional, Arechvo, Anastasija, additional, Syngelaki, Argyro, additional, Lloyd, David, additional, Zidere, Vita, additional, Vigneswaran, Trisha, additional, Miller, Owen, additional, Akolekar, Ranjit, additional, Nanda, Surabhi, additional, Nicolaides, Kypros, additional, Kainz, Bernhard, additional, Simpson, John M, additional, Hajnal, Jo V, additional, and Razavi, Reza, additional

Published
2024
Full Text
View/download PDF

16. Machine learning-enabled maternal risk assessment for women with pre-eclampsia (the PIERS-ML model): a modelling study

Author

Montgomery-Csobán, Tünde, primary, Kavanagh, Kimberley, additional, Murray, Paul, additional, Robertson, Chris, additional, Barry, Sarah J E, additional, Vivian Ukah, U, additional, Payne, Beth A, additional, Nicolaides, Kypros H, additional, Syngelaki, Argyro, additional, Ionescu, Olivia, additional, Akolekar, Ranjit, additional, Hutcheon, Jennifer A, additional, Magee, Laura A, additional, von Dadelszen, Peter, additional, Brown, Mark A., additional, Davis, Gregory K., additional, Parker, Claire, additional, Walters, Barry N., additional, Sass, Nelson, additional, Ansermino, J. Mark, additional, Cao, Vivien, additional, Cundiff, Geoffrey W., additional, von Dadelszen, Emma C.M., additional, Douglas, M. Joanne, additional, Dumont, Guy A., additional, Dunsmuir, Dustin T., additional, Hutcheon, Jennifer A., additional, Joseph, K.S., additional, Lalji, Sayrin, additional, Lee, Tang, additional, Li, Jing, additional, Lim, Kenneth I., additional, Lisonkova, Sarka, additional, Lott, Paula, additional, Menzies, Jennifer M., additional, Millman, Alexandra L., additional, Palmer, Lynne, additional, Payne, Beth A., additional, Qu, Ziguang, additional, Russell, James A., additional, Sawchuck, Diane, additional, Shaw, Dorothy, additional, Still, D. Keith, additional, Ukah, U. Vivian, additional, Wagner, Brenda, additional, Walley, Keith R., additional, Hugo, Dany, additional, Gruslin, The late Andrée, additional, Tawagi, George, additional, Smith, Graeme N., additional, Côté, Anne-Marie, additional, Moutquin, Jean-Marie, additional, Ouellet, Annie B., additional, Lee, Shoo K., additional, Duan, Tao, additional, Zhou, Jian, additional, Haniff, The late Farizah, additional, Mahajan, Swati, additional, Noovao, Amanda, additional, Karjalainend, Hanna, additional, Kortelainen, Alja, additional, Laivuori, Hannele, additional, Ganzevoort, J. Wessel, additional, Groen, Henk, additional, Kyle, Phillipa M., additional, Moore, M. Peter, additional, Pullar, Barbra, additional, Bhutta, Zulfiqar A., additional, Qureshi, Rahat N., additional, Sikandar, Rozina, additional, Bhutta, The late Shereen Z., additional, Cloete, Garth, additional, Hall, David R., additional, van Papendorp, The late Erika, additional, Steyn, D. Wilhelm, additional, Biryabarema, Christine, additional, Mirembe, Florence, additional, Nakimuli, Annettee, additional, Allotey, John, additional, Thangaratinam, Shakila, additional, Nicolaides, Kypros H., additional, de Swiet, Michael, additional, Magee, Laura A., additional, Walker, James J., additional, Robson, Stephen C., additional, Broughton-Pipkin, Fiona, additional, Loughna, Pamela, additional, Vatish, Manu, additional, Redman, Christopher W.G., additional, Barry, Sarah J.E., additional, Montgomery-Csobán, Tunde, additional, Tsigas, Eleni Z., additional, Woelkers, Douglas A., additional, Lindheimer, Marshall D., additional, Grobman, William A., additional, Sibai, Baha M., additional, Merialdi, Mario, additional, and Widmer, Mariana, additional

Published
2024
Full Text
View/download PDF

20. Screening for pregnancy complications at 11-13 weeks' gestation

Author

Syngelaki, Argyro

Subjects
618.3
Abstract

Background: The current approach to prenatal care, which was established more than 80 years ago, is characterised by a high concentration of visits in the third-trimester of pregnancy which implies that firstly, most complications occur at this late stage of pregnancy and secondly, most adverse outcomes are unpredictable during the first or even the second trimester. Objectives: The objective of this thesis is to provide evidence that most pregnancy complications are predictable as early as 12 weeks’ gestation. The pregnancy complications examined include fetal aneuploidies, fetal structural defects, preeclampsia, preterm birth, gestational diabetes mellitus and fetal macrosomia. Methods: I have critically examined fourteen articles reporting on screening for pregnancy complications at 11-13 weeks’ gestation, where more than 90,000 singleton pregnancies were prospectively assessed at 11-13 weeks’ gestation as part of a routine prenatal visit for screening for trisomy 21. We recorded a series of maternal characteristics and history, measured maternal weight and height, performed a detailed ultrasound examination of the fetus, measured maternal uterine artery Doppler pulsatility index and maternal mean arterial pressure and collected blood for analysis of biomarkers for prospective or retrospective analysis. All data were prospectively entered into our data base as well as the pregnancy outcomes as soon as they became available. Ethical approval was obtained for these studies. Multivariate regression analysis was used to define the contribution of each maternal characteristic and history in predicting each adverse outcome and those with a significant contribution formed an algorithm to estimate the background risk (a priori risk) for each one of these complications. The potential value of biophysical and biochemical markers in improving the performance of the a priori risk in predicting adverse pregnancy outcomes, was evaluated. Results: First trimester effective screening for adverse pregnancy outcomes was provided by a combination of maternal factors and biophysical or biochemical markers. The developed predictive models could correctly identify the vast majority of aneuploidies, early preeclampsia and more than half of the cases of spontaneous preterm birth and gestational diabetes. First trimester prediction of fetal macrosomia was less effective compared with other complications. First trimester examination of fetal anatomy was feasible resulting in a high detection of fetal non-chromosomal defects, including more than half of fetal cardiac defects. Conclusions: Assessment of the mother and fetus at 11-13 weeks’ gestation can provide effective early identification of the high risk group of pregnancies with fetal and maternal adverse outcomes.

Published
2015

29. Placental growth factor testing at 19–23 weeks of gestation as a guide to subsequent care in pregnancy: A prospective observational study.

Author

Magee, Laura A., Syngelaki, Argyro, Akolekar, Ranjit, von Dadelszen, Peter, and Nicolaides, Kypros H.

Subjects
*PLACENTAL growth factor, *PREGNANCY, *NEONATAL intensive care units, *FETAL growth retardation, *LONGITUDINAL method
Abstract

Objective: To determine whether serum placental growth factor (PlGF) at 19–23 weeks of gestation can improve the identification of risk for adverse outcomes. Design: Prospective observational cohort study. Setting: Two English maternity units. Population: Unselected singleton pregnancies attending routine ultrasound at 19–23 weeks of gestation. Methods: Outcomes ascertained by health record review. Diagnostic test properties evaluated clinical risk factors for pre‐eclampsia (according to National Institute of Care Excellence) or fetal growth restriction (according to Royal College of Obstetricians and Gynaecologists), low PlGF at 19–23 weeks of gestation (<5th percentile) or both. Main outcome measures: Pre‐eclampsia, gestational hypertension, stillbirth, birthweight below third percentile or neonatal intensive care unit (NICU) admission for ≥48 h. Results: In 30 013 pregnancies, risk factors were present in 9941 (33.1%), low PlGF was present in 1501 (5.0%) and both ('two‐stage' screening) were present in 547 (1.8%) pregnancies. Risk factors detected 41.7%–54.7% of adverse outcomes, and could not meaningfully revise the risk (all positive likelihood ratios, +LR, <5.0; all negative likelihood ratios, −LR, ≥0.2). Low PlGF detected 8.5%–17.4% of adverse outcomes, but meaningfully increased risks (other than NICU admission) associated with delivery <37 weeks of gestation (+LR = 5.03–15.55); all −LRs were ≥0.2. 'Two‐stage' screening detected 4.2%–8.9% of adverse outcomes, with meaningful +LRs (6.28–18.61) at <37 weeks of gestation, except for NICU admission of ≥48 h, which had an +LR of 7.56 at <34 weeks of gestation; all −LRs were ≥0.2. No screening strategy meaningfully increased or decreased the detection of adverse outcome risk at term. Conclusions: Clinical risk factor screening has a high screen‐positive rate and a poor detection of adverse outcomes. False positives cannot be reduced by PlGF testing at 19–23 weeks of gestation; therefore, this cannot be recommended as a useful strategy on its own. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

33. Early vaginal progesterone versus placebo in twin pregnancies for the prevention of spontaneous preterm birth: a randomized, double-blind trial

Author

Rehal, Anoop, Benkő, Zsófia, De Paco Matallana, Catalina, Syngelaki, Argyro, Janga, Deepa, Cicero, Simona, Akolekar, Ranjit, Singh, Mandeep, Chaveeva, Petya, Burgos, Jorge, Molina, Francisca S., Savvidou, Makrina, De La Calle, Maria, Persico, Nicola, Quezada Rojas, Maria Soledad, Sau, Ashis, Greco, Elena, O’Gorman, Neil, Plasencia, Walter, Pereira, Susana, Jani, Jacques C., Valino, Nuria, del Mar Gil, Maria, Maclagan, Kate, Wright, Alan, Wright, David, and Nicolaides, Kypros H.

Published
2021
Full Text
View/download PDF

37. Pregnancy--An Ideal Period to Identify Women at Risk for Chronic Hypertension.

Author

Charakida, Marietta, Wright, Alan, Magee, Laura A., Syngelaki, Argyro, von Dadelszen, Peter, Akolekar, Ranjit, Wright, David, and Nicolaides, Kypros H.

Abstract

BACKGROUND: Cardiovascular disease is the leading cause of mortality in women. Pregnancy is an ideal period to implement cardiovascular prevention strategies as women seek medical help. We aimed to develop a predictive model to identify women at increased risk for chronic hypertension (CH) based on information collected in the index pregnancy. METHODS: Cohort of 26 511 women seen in 2 consecutive pregnancies. Included were women without CH, with information on maternal characteristics and blood pressure at 11 to 13 weeks' gestation, and the development of preeclampsia or gestational hypertension (GH) in the index pregnancy. Logistic regression models were fitted for the prediction of the development of future CH by the 20th week of the subsequent pregnancy. The performance of screening and risk calibration of the model were assessed. RESULTS: In this study 1560 (5.9%) women developed preeclampsia or GH (index pregnancy), and 215 (0.8%) developed future CH, with a median of 3.0 years later. Predictors of development of future CH were maternal age, weight, and blood pressure; Black and South Asian ethnicity; family history of preeclampsia; parity; and development of preeclampsia or GH. Preeclampsia or GH detected 52.1% (45.2%-58.9%) of future CH. At a screen-positive rate of 10%, a model including maternal characteristics, early pregnancy blood pressure, and development of preeclampsia or GH detected 73.5% (67.1-79.3) of future CH. CONCLUSIONS: Early pregnancy maternal characteristics, blood pressure, and development of preeclampsia or GH identify three-fourths of women at risk for future CH. Our results offer an important preventative strategy for identifying women at increased risk of future CH, which is applicable worldwide. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

38. Relation of antepartum stillbirth to birthweight and gestational age: Prospective cohort study.

Author

Papastefanou, Ioannis, Ashoor, Ghalia, Syngelaki, Argyro, Akolekar, Ranjit, and Nicolaides, Kypros H.

Subjects
GESTATIONAL age, STILLBIRTH, BIRTH weight, PRENATAL care, SMALL for gestational age
Abstract

Objectives: To investigate the incidence of antepartum stillbirth in relation to the distribution of neonatal/fetal weight for different gestational ages. Design: Prospective observational cohort study. Setting: Obstetric ultrasound departments in two UK maternity hospitals. Population: 168 966 women with singleton pregnancies attending for routine antenatal care. Methods: We examined the incidence of antepartum stillbirths, within different birthweight and fetal weight percentile subgroups, conditioning for gestational age. Main outcome measures: Incidence of antepartum stillbirth. Results: The risk of stillbirth progressively increased for lower birthweight. Considering the 25–75th percentile as the reference category, the relative risks for stillbirth at <37 weeks' gestation were 7.6 (95% confidence interval [CI] 5.7–10.2) <1st percentile, 2.6 (95% CI 1.8–3.7) 1 to 10th percentile, 1.4 (95% CI 0.9–2.1) 10 to 25th percentile, 0.8 (95% CI 0.4–1.5) 75 to 90th percentile, 0.8 (95% CI 0.4–1.7) 90 to 99th percentile, 0.9 (95% CI 0.3–2.5) >99th percentile. The respective values for births at ≥37 weeks' gestation were 5.0 (95% CI 2.9–8.9), 2.1 (95% CI 1.4–3.3), 1.4 (95% CI 0.9–2.1), 1.2 (95% CI 0.7–1.8), 1.0 (95% CI 0.6–1.8) and 4.0 (95% CI 1.8–9.3). The incidence of stillbirth in ongoing low‐risk singleton pregnancies gradually increases for smaller fetuses at any gestational point. The higher incidence (5.56%) was evident for fetal weight <1st percentile between 24 and 28 weeks' gestation. Conclusion: Fetal weight and the weight of the stillborn have a continuous association with the incidence of antepartum stillbirth which is affected by gestational age. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

48. Aspirin for Evidence-Based Preeclampsia Prevention trial: effect of aspirin in prevention of preterm preeclampsia in subgroups of women according to their characteristics and medical and obstetrical history

Author

Poon, Liona C., Wright, David, Rolnik, Daniel L., Syngelaki, Argyro, Delgado, Juan Luis, Tsokaki, Theodora, Leipold, Gergo, Akolekar, Ranjit, Shearing, Siobhan, De Stefani, Luciana, Jani, Jacques C., Plasencia, Walter, Evangelinakis, Nikolaos, Gonzalez-Vanegas, Otilia, Persico, Nicola, and Nicolaides, Kypros H.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results